Jay T. Foust

Finance

Consumer Services

Health Technology

Profile

Jay T.
Foust served as Chairman at Cantex Pharmaceuticals, Inc. and as Director at RCT BioVentures.
He obtained an undergraduate degree from the University of Arizona in 2000.

Former positions of Jay T. Foust

Companies	Position	End
Cantex Pharmaceuticals, Inc. Cantex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cantex Pharmaceuticals, Inc. develops heparin to ameliorate cardiac ischemia-reperfusion injuries. It also develops medications to enhance the safety and effectiveness of existing cancer treatments. The firm provides Disulfiram + copper Chelate that includes non-overlapping cancer stem cell killing mechanisms of actions. The company was founded in 2013 by Thomas P. Kennedy, Neil William Flanzraich and Stephen G. Marcus and is headquartered in Weston, FL.	Chairman	-
RCT BioVentures RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona.	Corporate Officer/Principal	-

See the detail of Jay T. Foust's experience

Training of Jay T. Foust

University of Arizona

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jay T. Foust's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
RCT BioVentures RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona.	Finance
Cantex Pharmaceuticals, Inc. Cantex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cantex Pharmaceuticals, Inc. develops heparin to ameliorate cardiac ischemia-reperfusion injuries. It also develops medications to enhance the safety and effectiveness of existing cancer treatments. The firm provides Disulfiram + copper Chelate that includes non-overlapping cancer stem cell killing mechanisms of actions. The company was founded in 2013 by Thomas P. Kennedy, Neil William Flanzraich and Stephen G. Marcus and is headquartered in Weston, FL.	Health Technology